Genmab ponders next steps after preliminary cancer candidate results
Genmab and partner Abbvie are ready to confer with global health authorities about planning the next steps for their cancer drug.
by marketwire, translated by daniel pedersen
Biotech firm Genmab and partner Abbvie have reported topline results from a phase I/II study of candidate epcoritamab, a subcutaneous drug against large B-cell lymphoma (LBCL), the companies have announced in a joint press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab value drops by over USD 1.5bn after royalties defeat
For subscribers
Abbvie takes over Novo Holdings portfolio company
For subscribers
